Background:Soft-tissue sarcomas (STS) are a diverse group of malignancies that remain a diagnostic and therapeutic challenge. Relatively few reliable cell lines currently exist. Rapidly developing technology for genomic profiling with emerging insights into candidate functional (driver) aberrations raises the need for more models for in vitro functional validation of molecular targets.Methods:Primary cell culture was performed on STS tumours utilising a differential attachment approach. Cell lines were characterised by morphology, immunocytochemistry, proliferation assays, short tandem repeat (STR) and microarray-based genomic copy number profiling.Results:Of 47 STS cases of various subtypes, half formed adherent monolayers. Seven formed se...
Usage of cancer cell lines has repeatedly generated conflicting results provoked by differences amon...
Soft tissue sarcomas (STS) are challenging as they represent a morphologically and genetically heter...
Myxofibrosarcoma (MFS) belongs to the group of sarcoma tumors, which represent only 1% of the totali...
Background: Soft-tissue sarcomas (STS) are a diverse group of malignancies that remain a diagnostic ...
Sarcomas are rare mesenchymal malignant tumors with unique biological and clinical features. Given t...
Sarcomas are a very diverse group of rare, malignant tumors, consisting of more than 50 histological...
Soft tissue sarcomas (STSs) are an uncommon group of solid tumors that can arise throughout the huma...
Sarcomas are rare heterogenous malignancies of mesenchymal origin characterised by complex karyotype...
Sarcomas are rare heterogeneous malignancies of mesenchymal origin characterised by complex karyotyp...
Soft tissue sarcomas (STS) are a rare group of mesenchymal solid tumors with heterogeneous genetic p...
Soft tissue sarcomas (STSs) constitute a heterogenous group of highly aggressive tumors of mesenchym...
BACKGROUND: Heterogeneity and low incidence comprise the biggest challenge in sarcoma diagnosis and ...
Soft tissue sarcomas (STS) are a rare group of mesenchymal solid tumors with heterogeneous genetic p...
2011 February 1Soft-tissue sarcomas, which result in approximately 10,700 diagnoses and 3,800 deaths...
Synovial sarcoma is a rare translocation-driven cancer with poor survival outcomes, particularly in ...
Usage of cancer cell lines has repeatedly generated conflicting results provoked by differences amon...
Soft tissue sarcomas (STS) are challenging as they represent a morphologically and genetically heter...
Myxofibrosarcoma (MFS) belongs to the group of sarcoma tumors, which represent only 1% of the totali...
Background: Soft-tissue sarcomas (STS) are a diverse group of malignancies that remain a diagnostic ...
Sarcomas are rare mesenchymal malignant tumors with unique biological and clinical features. Given t...
Sarcomas are a very diverse group of rare, malignant tumors, consisting of more than 50 histological...
Soft tissue sarcomas (STSs) are an uncommon group of solid tumors that can arise throughout the huma...
Sarcomas are rare heterogenous malignancies of mesenchymal origin characterised by complex karyotype...
Sarcomas are rare heterogeneous malignancies of mesenchymal origin characterised by complex karyotyp...
Soft tissue sarcomas (STS) are a rare group of mesenchymal solid tumors with heterogeneous genetic p...
Soft tissue sarcomas (STSs) constitute a heterogenous group of highly aggressive tumors of mesenchym...
BACKGROUND: Heterogeneity and low incidence comprise the biggest challenge in sarcoma diagnosis and ...
Soft tissue sarcomas (STS) are a rare group of mesenchymal solid tumors with heterogeneous genetic p...
2011 February 1Soft-tissue sarcomas, which result in approximately 10,700 diagnoses and 3,800 deaths...
Synovial sarcoma is a rare translocation-driven cancer with poor survival outcomes, particularly in ...
Usage of cancer cell lines has repeatedly generated conflicting results provoked by differences amon...
Soft tissue sarcomas (STS) are challenging as they represent a morphologically and genetically heter...
Myxofibrosarcoma (MFS) belongs to the group of sarcoma tumors, which represent only 1% of the totali...